213 related articles for article (PubMed ID: 10741273)
1. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.
O'Byrne KJ; Dalgleish AG; Browning MJ; Steward WP; Harris AL
Eur J Cancer; 2000 Jan; 36(2):151-69. PubMed ID: 10741273
[TBL] [Abstract][Full Text] [Related]
2. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer.
Dalgleish AG; O'Byrne KJ
Adv Cancer Res; 2002; 84():231-76. PubMed ID: 11883529
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and cancer: the role of the immune response and angiogenesis.
Dalgleish AG; O'Byrne K
Cancer Treat Res; 2006; 130():1-38. PubMed ID: 16610701
[TBL] [Abstract][Full Text] [Related]
4. Response of tumour cells to hypoxia: role of p53 and NFkB.
Royds JA; Dower SK; Qwarnstrom EE; Lewis CE
Mol Pathol; 1998 Apr; 51(2):55-61. PubMed ID: 9713587
[TBL] [Abstract][Full Text] [Related]
5. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
6. [Chemokines, tumor growth and angiogenesis].
Bucova M
Bratisl Lek Listy; 2001; 102(1):22-7. PubMed ID: 11727709
[TBL] [Abstract][Full Text] [Related]
7. Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids.
Rose DP; Connolly JM
Nutr Cancer; 2000; 37(2):119-27. PubMed ID: 11142082
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression.
Aonuma M; Saeki Y; Akimoto T; Nakayama Y; Hattori C; Yoshitake Y; Nishikawa K; Shibuya M; Tanaka NG
Int J Exp Pathol; 1999 Oct; 80(5):271-81. PubMed ID: 10607018
[TBL] [Abstract][Full Text] [Related]
9. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenesis and anti-angiogenesis in human neoplasms. Recent developments and the therapeutic prospects].
Vacca A; Ribatti D; Pellegrino A; Dammacco F
Ann Ital Med Int; 2000; 15(1):7-19. PubMed ID: 10842887
[TBL] [Abstract][Full Text] [Related]
11. Mast cell contribution to angiogenesis related to tumour progression.
Ribatti D; Crivellato E; Roccaro AM; Ria R; Vacca A
Clin Exp Allergy; 2004 Nov; 34(11):1660-4. PubMed ID: 15544587
[TBL] [Abstract][Full Text] [Related]
12. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
13. Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis.
Crivellato E; Nico B; Ribatti D
Cancer Lett; 2008 Sep; 269(1):1-6. PubMed ID: 18450371
[TBL] [Abstract][Full Text] [Related]
14. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells.
Murono S; Inoue H; Tanabe T; Joab I; Yoshizaki T; Furukawa M; Pagano JS
Proc Natl Acad Sci U S A; 2001 Jun; 98(12):6905-10. PubMed ID: 11381123
[TBL] [Abstract][Full Text] [Related]
15. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C; Dormond O; Mariotti A
Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis in chronic liver disease and its complications.
Coulon S; Heindryckx F; Geerts A; Van Steenkiste C; Colle I; Van Vlierberghe H
Liver Int; 2011 Feb; 31(2):146-62. PubMed ID: 21073649
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenesis and immune suppression: yin and yang of tumor progression?].
Szala S
Postepy Hig Med Dosw (Online); 2009 Dec; 63():598-612. PubMed ID: 20009124
[TBL] [Abstract][Full Text] [Related]
18. Chronic immune activation and inflammation as the cause of malignancy.
O'Byrne KJ; Dalgleish AG
Br J Cancer; 2001 Aug; 85(4):473-83. PubMed ID: 11506482
[TBL] [Abstract][Full Text] [Related]
19. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
